LEADER 03717oam  2200637   450 
001 9910137199003321
005 20230803213815.0
035   $a(CKB)3710000000526112
035   $a(SSID)ssj0001666301
035   $a(PQKBManifestationID)16454632
035   $a(PQKBTitleCode)TC0001666301
035   $a(PQKBWorkID)15000128
035   $a(PQKB)10195562
035   $a(WaSeSS)IndRDA00056513
035   $a(oapen)https://directory.doabooks.org/handle/20.500.12854/43405
035   $a(EXLCZ)993710000000526112
100   $a20160829h20142014  uy             0
101 0 $aeng
135   $aurmn#---|||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 00$aClinical use of biomarkers in neurodegenerative disorders /$ftopic editor Manuel Menéndez-González
210   $cFrontiers Media SA$d2014
210  1$aLausanne, Switzerland :$cFrontiers Media SA,$d2014.
210  4$aŠ2014
215   $a1 online resource (122 pages) $cillustrations; digital, PDF file(s)
225 0 $aFrontiers research topics
300   $aBibliographic Level Mode of Issuance: Monograph
311   $a2-88919-400-0 
320   $aIncludes bibliographical references.
330   $aThe world has a rapidly ageing population. Neurodegenerative diseases (ND) are strongly linked with age, with older citizens more at risk. Therefore the prevalence of ND is increasing dramatically. The major problem with ND is its difficulty to be diagnosed early. The goal of biomarker characterization is to increase certainty that a person has or does not have underlying pathology. During last decades, many research projects where focused on research on biomarkers for ND and this research has blasted into hundreds of scientific articles. However, few studies assessed their use in real clinical practice conditions. This Frontiers Research Topic is focused in the use of biomarkers for neurodegenerative disorders in the clinical setting. Topics include the use of biomarkers in the differential diagnosis of ND, the use of biomarkers to assess the risk of conversion from preclinical conditions, the use of biomarkers to follow up of clinical conditions and studies comparing biomarkers. We challenge to publish studies not only for the more frequent and more studied ND (Alzheimer?s and Parkinson?s diseases), but also for other less known ND such as prion diseases, motor neurone diseases, Huntington?s disease, spinocerebellar ataxia or spinal muscular atrophy among others. Biomarkers are very different in nature - from neuroimaging techniques to molecular parameters to be determined in the biochemical laboratory-. We welcome manuscripts reporting all kind of biomarkers since we wish to join and show together studies from different domains and thus give a perspective throughout the whole spectrum of research on biomarkers for ND.
606   $aNeurology
606   $aNeurology$2HILCC
606   $aMedicine$2HILCC
606   $aHealth & Biological Sciences$2HILCC
610   $aNeurodegenerative Diseases
610   $aneurodegenerative disease
610   $aParkinson's disease
610   $aMTAi
610   $abiomarker
610   $aHuntington's disease
610   $aCSF biomarkers
610   $aFrontotemporal dementia (FTD)
615  0$aNeurology.
615  7$aNeurology
615  7$aMedicine
615  7$aHealth & Biological Sciences
700   $aManuel Menendez-Gonzalez$4auth$01366918
702   $aMenéndez-González$b Manuel
801  0$bPQKB
801  2$bUkMaJRU
906   $aBOOK
912   $a9910137199003321
996   $aClinical use of biomarkers in neurodegenerative disorders$93408234
997   $aUNINA